Refeyn continues participation in NIIMBL consortium tackling AAV purification

Bio‑Techne and Refeyn close critical gap in bispecific antibody and biosimilar characterization

Refeyn and Bio-Techne close a critical gap in bispecific antibody and biosimilar characterization

Refeyn launches MyMass™ mass photometer

Leading CROs and CDMOs turn to mass photometry for rapid protein, mRNA and viral vector analytics

Upstream AAV characterization powered by mass photometry

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Refeyn Ltd recognized as a Top Employer for 2026 in the UK

Eight ways mass photometry is accelerating biological discovery

Refeyn announces appointment of Non-Executive Director